TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
LONDON - Futura Medical (TASE:BLWV) plc (AIM:FUM), a company specializing in the development of sexual health products, has announced the appointment of Panmure Liberum as its sole broker, effective immediately. The announcement made today also confirms that Panmure Liberum will maintain its position as the company’s Nominated Adviser.
The consumer healthcare company, known for its Eroxon product, focuses on the global commercialization of innovative and clinically proven sexual health products. Eroxon is a topical gel treatment for erectile dysfunction (ED) that has garnered attention for being the only over-the-counter product of its kind that can facilitate an erection within ten minutes.
Futura Medical has established itself in the sexual health market with distribution partners across major consumer markets, including Haleon in the U.S. and Cooper Consumer Health in Europe. Their products cater to a significant demographic, with ED affecting 1 in 5 men globally and sexual dysfunction symptoms prevalent in 60% of women, many of whom do not seek professional help.
The company’s portfolio, including Eroxon and other products like WSD4000 and Eroxon Intense, aims to address the unmet needs within the sexual health sphere. Eroxon, in particular, has received industry recognition, winning two healthcare awards to date.
This strategic move to consolidate brokerage services under Panmure Liberum is part of Futura’s ongoing efforts to strengthen its financial and advisory framework. The appointment is based on a press release statement from Futura Medical plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.